28 Jun

Precision Bio Lands $110M as Gene-Edited Cell Therapy Nears Clinic

DNA Double Helix

While CRISPR has grabbed the lion’s share of gene-editing headlines, Precision BioSciences has used its own gene-editing technology to quietly build a pipeline of products for both agriculture and human health. The Durham, NC company is now preparing to start testing a gene-edited cell therapy for cancer in humans and it has raised $110 million to support its efforts.

Precision Bio said Wednesday that it will apply the new capital, a Series B round of funding, toward clinical trials testing its cell therapy. The company also says it will ramp up pre-clinical work on a gene therapy program, and bring a… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

27 Jun

GBT Eyes Fast Nod for Sickle Cell Drug but Won’t Use Patient-Reported Data

Global Blood Therapeutics hasn’t finished testing its treatment for sickle cell disease, but the South San Francisco, CA-based company thinks it can get a fast-track approval for the once-a-day pill, voxelotor, from the FDA.

That was the company’s message this morning when it presented results from the first half of its key Phase 3 study, known as HOPE. Part A of the study continued voxelotor’s track record from previous studies. In two different doses, the drug significantly boosted levels of the protein hemoglobin, which carries oxygen and is crucial to the healthy function of red blood cells. The news bumped Global… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

27 Jun

Effects

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: PADR-EF-2018Pillar: Preparatory Action on Defence Research (PADR)Opening Date: Deadline: Thu, 28 Jun 2018 17:00:00 (Brussels local time)Modification Date: Wed, 27 Jun 2018Latest information: We have updated the document with the topic relatedfrequently asked questions- see the topic conditions section below.

27 Jun

New Report Offers “Distorted View” of Biopharma Industry

This week, the Minority Staff of the U.S. Senate Committee on Finance released a report entitled, “A Tangled Web: An Examination of the Drug Supply and Payment Chains.” The report is the latest to look at the nation’s complex drug cost ecosystem.

More patients are finding that what they have to pay for prescription drugs is simply unaffordable. That’s why BIO has repeatedly called on policymakers to advance reforms that will help provide all patients affordable access to the medicines they need. Real reform requires a holistic approach, one that recognizes the roles insurers, pharmacy benefits managers, hospitals and other health care actors play in determining what people pay for their prescription drugs.

Unfortunately, this report provides a distorted view of the biopharmaceutical industry. For example, it doesn’t mention the fact that 90% of all biopharmaceutical companies are unprofitable and most biotech companies are small businesses. It also fails to recognize that when compared to other industries, the biotech sector collectively ranks near the bottom in terms of profitability. Finally, it gives scant attention to the tremendous value biopharmaceutical innovation provides patients and our broader health care system.

Biopharmaceutical innovators invest enormous amounts of time and resources bringing new cures and treatments to market, yet a large share of what’s spent each year on prescription drugs goes to insurance companies and other middlemen. While we disagree with the conclusions in this report, we have long been encouraging policymakers to carefully review the complex way drugs are delivered to patients. We believe such an effort will ultimately lead to real solutions that provide all patients access to the medicines they need at a cost they can afford.

26 Jun

As More Countries Adopt Crop Biotechnology, Farm Families and the Environment Benefit

Biotech crops in the last 22 years have brought enormous benefits to the environment, health of humans and animals, and contributions to the improvement of socio economic conditions of farmers and the general public, according to a new report issued today by the International Service for the Acquisition of Agri-biotech Applications (ISAAA).

The ISAAA report shows the global biotech crop area increased in 2017 by 3 percent or 4.7 million hectares or 11.6 million acres; Global economic gains contributed by biotech crops in the last 21 years (1996-2016) have amounted to US $186.1 billion economic benefits to more than 16 to 17 million farmers, 95 percent of whom come from developing countries.

As more developing countries, now 19 in total including India, Pakistan, Brazil, Bolivia, Sudan, Mexico, Colombia, Vietnam, Honduras, and Bangladesh have increased their biotech crop area and continue to allow farmers to adopt biotechnology in food production, smallholder farmers see the direct improvements this offers, allowing them to provide better lives for themselves and their families.

Developing countries now account for 53 percent of the global biotech area planted.

The ISAAA report was released in conjunction with a similar study by PG Economics, Ltd. Both studies highlight and quantify the continued social, environmental and economic benefits of the global adoption of biotechnology in agriculture.

From 1996-2016, PG Economics reported biotech crops provided $186.1 billion in economic gains to some 17 million farmers, many of whom are female, smallholder farmers solely responsible for the livelihood of their families and communities.

“Global food insecurity is a huge problem in developing countries, with around 108 million people in food crisis-affected countries still at risk or experiencing food insecurity,” said Graham Brookes, Director of PG Economics and co-author of the socio-economic and environmental impact paper. “We have seen for more than 20 years now how crop biotechnology adoption in developing countries has contributed to higher yields, more secure production, and increased incomes greatly contributing to decreasing poverty, hunger and malnutrition in some regions of the globe most prone to these challenges.”

The PG Economics study also shows great strides have already been made to reduce the footprint of agriculture and in mitigating and adapting to climate change. The latest study highlights how biotech use in agriculture continues to contribute to reducing greenhouse gas emissions.

Highlights from the PG Economics report include:

  • In 2016, the GM crop-related carbon dioxide emission savings from reduced fuel use and additional soil carbon sequestration were equal to the removal of 16.75 million cars from the roads.
  • Advances in biotech crops allow farmers to use insecticides and herbicides more strategically, reducing the environmental impact associated with their use by 18.4 percent on GM crop areas since 1996.
  • In 2016, the direct global farm income benefit from GM crops was $18.2 billion, equal to an average increase in income of $102/hectare. Since 1996, farm incomes have increased by $186.1 billion.
  • Biotechnology remains a strong investment for farmers. In terms of farmer investment, for each dollar invested in biotech crop seeds, farmers gained an average $3.49.

Additional highlights from ISAAA’s 2017 report include:

  • In 2017, 67 countries used biotech crops.

    – This includes 24 countries in total that grew biotech crops, including 19 developing and five industrial countries;

    – and an additional 43 non-planting countries that formally regulate the importation and use of biotech crops for food, feed and processing

  • Top five countries (USA, Brazil, Argentina, Canada and India) planted 91.3 percent of the global biotech crop area of 189.8 million hectares or 469 million acres.
  •  Biotech crops increased ~112-fold from 1996, the fastest adopted crop technology in the world; accumulated biotech area at 2.3 billion hectares or 5.7 billion acres.

 

The complementary studies – PG Economics’ “GM Crops: Global Socio-Economic and Environmental Impacts 1996-2016” and ISAAA’s Global Status of Commercialized Biotech/GM Crops: 2017” – examine the continued widespread adoption of global crop biotechnology, and the significant positive socio-economic and environmental impacts of this adoption by farmers and communities around the globe.

The associated two papers in the peer review journal GM Crops and Food are available, with open access, at: www.tandfonline.com/doi/full/10.1080/21645698.2018.1464866 and www.tandfonline.com/doi/full/10.1080/21645698.2018.1476792

26 Jun

Helix Expands Real-World and Online Footprint with HumanCode Deal

Helix, which runs an online outlet for products based on customer DNA, has bought HumanCode, one of the app makers that contributes to its store. Denver-based HumanCode makes BabyGlimpse, which shows couples genetic traits that they might pass on to their children; and DNA Passport, which the company calls a “starter kit” to explore one’s own genetic code.

San Carlos, CA-based Helix did not say how much it is paying for HumanCode. The deal reunites Helix’s CEO Robin Thurston and HumanCode’s executive team. HumanCode CEO Chris Glode and VP of engineering Ryan Trunck were with Thurston at the fitness app maker… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

26 Jun

Research Headlines – What the heart wants …smarter monitoring systems

[Source: Research & Innovation] Abnormal heart rhythm is a major cause of cardiovascular disease and death in Europe. An EU-supported programme has made several advances in wearable technology to more comfortably monitor the heart over longer periods, in the hope of saving lives and cutting treatment costs.

26 Jun

Bio-Techne to Acquire Liquid Biopsy Firm Exosome Diagnostics for $250M

Exosome Diagnostics, a company that has developed technology to test for disease by analyzing blood and other bodily fluids, has agreed to be acquired by Bio-Techne in a $250 million cash deal.

If Waltham, MA-based Exosome hits certain unspecified milestones, the company could receive up to $325 million more, the companies announced Monday after the market close. Bio-Techne (NASDAQ: TECH), based in Minneapolis, says it will finance the transaction with cash on hand and a revolving line of credit that it expects to obtain. The companies expect to close the deal by early August.

Exosome Diagnostics develops and sells diagnostics… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

25 Jun

Better Health and care, economic growth and sustainable health systems

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-SC1-BHC-2018-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Tue, 2 Oct 2018 17:00:00 (Brussels local time)Modification Date: Mon, 25 Jun 2018Latest information: Generalised feedback for successful applicants after stage 1 (topic SC1-BHC-15-2018 that closed on 06 February 2018) with information and tips for preparing the full proposal, is now available under the “Topic conditions and documents” section on the topic page.

25 Jun

Humacyte Promotes Jeffrey Lawson to Chief Executive

Jeffrey Lawson has been appointed CEO of regenerative medicine company Humacyte. Lawson had been chief medical officer of the Research Triangle Park, NC, company since 2015. Lawson’s experience includes several roles at Duke University Medical Center. Former CEO Carrie Cox has taken on the role of executive chairman. Humacyte has developed a way to grow veins in a laboratory. The company is currently in Phase 3 studies testing these veins as an alternative to synthetic blood vessels for kidney failure patients.

UNDERWRITERS AND PARTNERS